Biogen Inc. (BIIB)
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BIIB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $36.89B
- P/E (TTM)
- 108.05
- Forward P/E
- 15.37
- EPS (TTM)
- $2.31
- Dividend yield
- None
- 52-week range
- 160.36 – 261.00
- Day range
- 248.04 – 253.00
- Volume / Avg
- 1.13M / 1.10M
- Beta
- —
- Shares outstanding
- 147.82M
52-week range
BIIB stock today
On Nov 20, BIIB ended the session at $249.59, adding $2.46 (1.00%), versus the S&P 500's 3.70% decline. At this level, BIIB sits near the top of its 52-week range of $160.36 to $261.00: 4.4% below the high, set on Nov 9, 2026 and 55.6% above the low. BIIB is up 41.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 42.4%.
At 108.0x trailing earnings, Biogen trades above the peer-group median of 22.8x. Its forward P/E of 15.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Biogen
Company profileBiogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Christopher A. Viehbacher
- Headquarters
- Cambridge, MA
- Employees
- 7,500
- Website
- biogen.com
Financial highlights
Full financialsIn fiscal 2025, Biogen generated $9.89 billion in revenue, up 2.2% from fiscal 2024. Net income was $1.29 billion (-20.8% year over year), for a net margin of 13.1% versus a median of 16.9% in the prior 5 years. Gross margin was 75.7% (down from 76.1%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Growth | +2.22% | -1.62% | -3.32% | -7.36% | -18.32% |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| EPS (diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
Analyst forecast
ForecastConsensus (36 analysts)
buy
Avg. price target
$268.26+7.48%
- Strong buy 4
- Buy 21
- Hold 10
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.14 vs $2.06
- Surprise
- -106.80%
BIIB news
All BIIB news- Biogen: Why I'm Still Bullish Despite Market TurmoilSeeking Alpha
- Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike DealsNasdaqABBV, BIIB, BMY, ENLV
- Biogen: M&A Growth And Alzheimer's Progress Are Now Priced In (Rating Downgrade)Seeking Alpha
- Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026GlobeNewswire
- Biogen, Eisai Reports Three-Year Real-World LEQEMBI Data Showing Slower Alzheimer's ProgressionNasdaqBIIB, ET
- New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026GlobeNewswire
- Biogen Reports Two-Year Data Showing Continued Benefit Of Dianersen In Early Alzheimer's DiseaseNasdaqBIIB, HEI.A
- Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019Nasdaq
Biogen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RVMDRevolution Medicines Inc. | 161.20 | +1.11% | $34.87B | vs BIIB |
| BNTXBioNTech SE ADR | 80.96 | -0.52% | $20.07B | vs BIIB |
| EXELExelixis Inc. | 64.63 | -1.82% | $15.77B | vs BIIB |
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs BIIB |
| ARGXargenx SE ADR | 925.70 | -1.73% | $58.21B | vs BIIB |
| TECHBio-Techne Corp | 72.67 | -0.04% | $11.42B | vs BIIB |
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs BIIB |
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs BIIB |
Indexes, lists and sector
Index membership
Biogen stock FAQ
What is Biogen's stock price today?
BIIB last traded at $249.59 as of Nov 20, 4:00 PM EST, up 1.00% on the day. Prices are delayed at least 15 minutes.
Does Biogen pay a dividend?
No. Biogen does not currently pay a regular cash dividend.
What is BIIB's P/E ratio?
BIIB trades at a trailing P/E ratio of 108.05 and a forward P/E of 15.37, compared with a median of 22.8 for its closest peers.
Is Biogen in the S&P 500?
Yes. Biogen (BIIB) is a constituent of the S&P 500 index.
Who is Biogen's CEO?
Mr. Christopher A. Viehbacher is the chief executive officer of Biogen Inc., which has about 7,500 employees.
Has BIIB ever split its stock?
Yes. The most recent BIIB stock split was a 3-for-1 split on Jan 18, 2001, one of 2 splits on record.
What is the BIIB 52-week high?
The 52-week high for BIIB is $261.00 and the 52-week low is $160.36. The stock is currently 4.4% below its high.